Outcome, toxicity profile and cost analysis of autologous stem cell mobilization

Bone Marrow Transplantation

Volumn 46, Issue 8, 2011, Pages 1084-1088

  Jagasia, M H ^a   Savani, B N ^a   Neff, A ^a   Dixon, S ^a   Chen, H ^a   Pickard, A S ^b,c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b Second City Outcomes Research LLC   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

autologous; cost; economics; plerixafor; stem cell

Indexed keywords

CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; BONE PAIN; CD34 SELECTION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DIARRHEA; DRUG COST; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG RESPONSE; FEBRILE NEUTROPENIA; FEMALE; HOSPITALIZATION COST; HUMAN; INFECTION; LEUKAPHERESIS; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYELOMA; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEM CELL MOBILIZATION; THERAPY EFFECT; TREATMENT PLANNING; VOMITING;

AGED; CYCLOPHOSPHAMIDE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 80051693613     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.254     Document Type: Article

References (15)

1. Bensinger W, DiPersio JF, McCarty JM. Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant 2009; 43: 181-195.
2. Moskowitz CH, Glassman JR, Wuest D, Maslak P, Reich L, Gucciardo A et al. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clin Cancer Res 1998; 4: 311-316. (Pubitemid 28122743)
3. Ashihara E, Shimazaki C, Okano A, Hatsuse M, Okamoto A, Shimura K et al. Infusion of a high number of CD34+ cells provides a rapid hematopoietic recovery and cost savings in autologous peripheral blood stem cell transplantation. Jpn J Clin Oncol 2002; 32: 135-139. (Pubitemid 41289012)
4. Schulman KA, Birch R, Zhen B, Pania N, Weaver CH. Effect of CD34(+) cell dose on resource utilization in patients after high-dose chemotherapy with peripheral-blood stem-cell support. J Clin Oncol 1999; 17: 1227.
5. Meehan KR, Hill JM, Patchett L, Webber SM, Wu J, Ely P et al. Implementation of peripheral blood CD34 analyses to initiate leukapheresis: marked reduction in resource utilization. Transfusion 2006; 46: 523-529.
6. Gertz MA, Wolf RC, Micallef IN, Gastineau DA. Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma. Bone Marrow Transplant 2010; 45: 1396-1403.
7. Vose JM, Ho AD, Coiffier B, Corradini P, Khouri I, Sureda A et al. Advances in mobilization for the optimization of autologous stem cell transplantation. Leuk Lymphoma 2009; 50: 1412-1421.
8. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720-5726.
9. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 4767-4773.
10. Tricot G, Cottler-Fox MH, Calandra G. Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization. Bone Marrow Transplant 2010; 45: 63-68.
11. Nazha A, Cook R, Vogl D, Mangan P, Hummel K, Cunningham K et al. Plerixafor and G-CSF Versus Cyclopho-sphamide and G-CSF for Stem Cell Mobilization in Patients with Multiple Myeloma. Blood 2009; 114: abstract 844.
12. Shaughnessy P, Islas-Ohlamayer M, Murphy J, Houghman M, MacPherson J, Winkler K et al. Plerixafor Plus G-CSF Compared to Chemotherapy Plus G-CSF for Mobilization of Autologous CD34+ Cells Resulted in Similar Cost but More Predictable Days of Apheresis and Less Hospitalization. Blood 2009; 114: abstract 897.
13. Campen C, Armstrong E, Christian J, Hadeed S, Yeager A. Comparative Cost-effectiveness of prelixafor plus granulocyte-colony stimulating factor versus cyclophosphamide plus granulocyte-colony stimulating factor for autologous peripheral blood stem cell mobilization in patients with non-hodgkin's lymphoma. Biol Blood Marrow Transplant 2010; 16: s206.
14. Jantunen E, Putkonen M, Nousiainen T, Pelliniemi TT, Mahlamaki E, Remes K. Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma. Bone Marrow Transplant 2003; 31: 347-351. (Pubitemid 36410680)
15. Fitoussi O, Perreau V, Boiron JM, Bouzigon E, Cony-Makhoul P, Pigneux A et al. A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients. Bone Marrow Transplant 2001; 27: 837-842. (Pubitemid 32496417)